ReviewMethodist DeBakey cardiovascular journal2026
Genetic and Conventional Risk Stratification Are Complementary for Primary Prevention of CAD.
Review in Methodist DeBakey cardiovascular journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary prevention of coronary artery disease (CAD) needs to be initiated early in young asymptomatic individuals (20s, 30s). Current pooled cohort equation (PCE) risk stratification for CAD is based on conventional risk factors often not present until the fifth or sixth decade. Genetics accounts for 50% of risk for CAD. The number of DNA risk variants present in an individual, referred to as a polygenic risk score (PRS), can be used to risk stratify young asymptomatic individuals since the PRS is derived from DNA risk variants that are randomized at conception and can be determined at birth or anytime thereafter. The PRS does not change in one's lifetime; it has been evaluated in over 1 million individuals, and the top 20% have a threefold increased risk for CAD. The genetic risk for CAD as detected by PRS is independent of and complementary to conventional risk stratification. Genetic risk has been shown to be reduced by lowering plasma LDL-C, adopting a healthy lifestyle, and increasing physical activity. The minimal threshold required for clinical manifestations-as determined by mg per years of exposure to plasma LDL-C-is suggested to be around 5,000 mg years. This is considered the minimum clinical threshold based on a 1% incidence of myocardial infarction in the United States (US) at age 40 years and an average plasma LDL-C of 125 mg/dL, with a product of 40 × 125 resulting in 5,000 mg years. Utilizing PRS to detect candidates at increased risk for CAD while in their 30s, followed by an annual injection of a long-acting agent such as inclisiran to reduce plasma LDL-C in the range of 60 mg/dL, has the potential to delay the onset of a first myocardial infarction until age 80 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.